Nonalcoholic fatty future disease

Metabolism: Clinical and Experimental

Volumn 65, Issue 8, 2016, Pages 1007-1016

  Polyzos, Stergios A ^a   Mantzoros, Christos S ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Noninvasive indices; Simple steatosis; Treatment

Indexed keywords

IN VITRO STUDY; METABOLIC DISORDER; METABOLISM; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE MODEL; FATTY LIVER; HUMAN; PATHOLOGY;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; FATTY LIVER; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84955238943     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2015.12.009     Document Type: Review

References (46)

1. [1] Rinella, M.E., Nonalcoholic fatty liver disease: a systematic review. JAMA 313 (2015), 2263–2273.
2. [2] Ludwig, J., Viggiano, T.R., McGill, D.B., et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55 (1980), 434–438.
3. [3] Fazel, Y., Koenig, A.B., Sayiner, M., et al. Epidemiology and natural history of nonalcoholic fatty liver disease. Metabolism 65 (2016), 1017–1025.
4. [4] Khan, R.S., Newsome, P.N., Non-alcoholic fatty liver disease and liver transplantation. Metabolism 65 (2016), 1096–1108.
5. [5] Polyzos, S.A., Kountouras, J., Zavos, C., The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in nonalcoholic fatty liver disease. Hip, 13, 2009, 127.
6. [6] Polyzos, S.A., Mantzoros, C.S., An update on the validity of irisin assays and the link between irisin and hepatic metabolism. Metabolism 64 (2015), 937–942.
7. [7] Chung, M., Ma, J., Patel, K., et al. Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. Am J Clin Nutr 100 (2014), 833–849.
8. [8] Polyzos, S.A., Kountouras, J., Zavos, C., Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 72 (2009), 299–314.
9. [9] Petrasek, J., Csak, T., Ganz, M., et al. Differences in innate immune signaling between alcoholic and non-alcoholic steatohepatitis. J Gastroenterol Hepatol 28:Suppl. 1 (2013), 93–98.
10. [10] Goel, A., Gupta, M., Aggarwal, R., Gut microbiota and liver disease. J Gastroenterol Hepatol 29 (2014), 1139–1148.
11. [11] Polyzos, S.A., Kountouras, J., Papatheodorou, A., et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism 62 (2013), 121–126.
12. [12] Polyzos, S.A., Kountouras, J., Deretzi, G., et al. The emerging role of endocrine disruptors in pathogenesis of insulin resistance: a concept implicating nonalcoholic fatty liver disease. Curr Mol Med 12 (2012), 68–82.
13. [13] Polyzos, S.A., Mantzoros, C.S., Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism 63 (2014), 161–167.
14. [14] Polyzos, S.A., Kountouras, J., Zavos, C., et al. Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol 46 (2012), 272–284.
15. [15] Chalasani, N., Younossi, Z., Lavine, J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55 (2012), 2005–2023.
16. [16] Mahady, S.E., George, J., Exercise and diet in the management of nonalcoholic fatty liver disease. Metabolism 65 (2016), 1172–1182.
17. [17] Egnatchik, R.A., Leamy, A.K., Noguchi, Y., et al. Palmitate-induced activation of mitochondrial metabolism promotes oxidative stress and apoptosis in H4IIEC3 rat hepatocytes. Metabolism 63 (2014), 283–295.
18. [18] Hao, L., Ito, K., Huang, K.H., et al. Shifts in dietary carbohydrate-lipid exposure regulate expression of the non-alcoholic fatty liver disease-associated gene PNPLA3/adiponutrin in mouse liver and HepG2 human liver cells. Metabolism 63 (2014), 1352–1362.
19. [19] Ganji, S.H., Kashyap, M.L., Kamanna, V.S., Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: impact on non-alcoholic fatty liver disease. Metabolism 64 (2015), 982–990.
20. [20] Lee, J., Hong, S.W., Park, S.E., et al. Exendin-4 regulates lipid metabolism and fibroblast growth factor 21 in hepatic steatosis. Metabolism 63 (2014), 1041–1048.
21. [21] Xia, S.F., Duan, X.M., Hao, L.Y., et al. Role of thyroid hormone homeostasis in obesity-prone and obesity-resistant mice fed a high-fat diet. Metabolism 64 (2015), 566–579.
22. [22] Pereira, S., Breen, D.M., Naassan, A.E., et al. In vivo effects of polyunsaturated, monounsaturated, and saturated fatty acids on hepatic and peripheral insulin sensitivity. Metabolism 64 (2015), 315–322.
23. [23] Lin, C.I., Huang, W.C., Chen, W.C., et al. Effect of whole-body vibration training on body composition, exercise performance and biochemical responses in middle-aged mice. Metabolism 64 (2015), 1146–1156.
24. [24] Yang, S.J., Lim, Y., Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation. Metabolism 63 (2014), 693–701.
25. [25] Brandt, C., Hansen, R.H., Hansen, J.B., et al. Over-expression of follistatin-like 3 attenuates fat accumulation and improves insulin sensitivity in mice. Metabolism 64 (2015), 283–295.
26. [26] Jeon, B.H., Lee, Y.H., Yun, M.R., et al. Increased expression of ATP-binding cassette transporter A1 (ABCA1) as a possible mechanism for the protective effect of cilostazol against hepatic steatosis. Metabolism 64 (2015), 1444–1453.
27. [27] Fu, L., Bruckbauer, A., Li, F., et al. Interaction between metformin and leucine in reducing hyperlipidemia and hepatic lipid accumulation in diet-induced obese mice. Metabolism 64 (2015), 1426–1434.
28. [28] Lees, E.K., Krol, E., Shearer, K., et al. Effects of hepatic protein tyrosine phosphatase 1B and methionine restriction on hepatic and whole-body glucose and lipid metabolism in mice. Metabolism 64 (2015), 305–314.
29. [29] Liu, X., Hamnvik, O.P., Chamberland, J.P., et al. Circulating alanine transaminase (ALT) and gamma-glutamyl transferase (GGT), but not fetuin-a, are associated with metabolic risk factors, at baseline and at two-year follow-up: the prospective Cyprus metabolism study. Metabolism 63 (2014), 773–782.
30. [30] Pan, L.L., Zhang, H.J., Huang, Z.F., et al. Intrahepatic triglyceride content is independently associated with chronic kidney disease in obese adults: a cross-sectional study. Metabolism 64 (2015), 1077–1085.
31. [31] Mantovani, A., Pernigo, M., Bergamini, C., et al. Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism 64 (2015), 879–887.
32. [32] Polyzos, S.A., Kountouras, J., Anastasilakis, A.D., et al. Irisin in patients with nonalcoholic fatty liver disease. Metabolism 63 (2014), 207–217.
33. [33] Dai, Y.N., Zhu, J.Z., Fang, Z.Y., et al. A case–control study: association between serum neuregulin 4 level and non-alcoholic fatty liver disease. Metabolism 64 (2015), 1667–1673.
34. [34] Viitasalo, A., Atalay, M., Pihlajamaki, J., et al. The 148 M allele of the PNPLA3 gene is associated with plasma irisin levels in a population sample of caucasian children: the PANIC study. Metabolism 64 (2015), 793–796.
35. [35] Regnell, S.E., Peterson, P., Trinh, L., et al. Magnetic resonance imaging reveals altered distribution of hepatic fat in children with type 1 diabetes compared to controls. Metabolism 64 (2015), 872–878.
36. [36] Oberbach, A., Neuhaus, J., Inge, T., et al. Bariatric surgery in severely obese adolescents improves major comorbidities including hyperuricemia. Metabolism 63 (2014), 242–249.
37. [37] Wree, A., Schlattjan, M., Bechmann, L.P., et al. Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients. Metabolism 63 (2014), 1542–1552.
38. [38] Marchesini, G., Brizi, M., Bianchi, G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (2001), 1844–1850.
39. [39] Oni, E.T., Agatston, A.S., Blaha, M.J., et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?. Atherosclerosis 230 (2013), 258–267.
40. [40] Charlton, M.R., Burns, J.M., Pedersen, R.A., et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141 (2011), 1249–1253.
41. [41] Younossi, Z.M., Otgonsuren, M., Henry, L., et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 62 (2015), 1723–1730.
42. [42] Udompap, P., Kim, D., Kim, W.R., Current and future burden of chronic nonmalignant liver disease. Clin Gastroenterol Hepatol 13 (2015), 2031–2041.
43. [43] Rinella, M.E., Lominadze, Z., Loomba, R., et al. Practice patterns in NAFLD and NASH: real life differs from published guidelines. Ther Adv Gastroenterol, 2015, 10.1177/1756283X15611581.
44. [44] Bergqvist, C.J., Skoien, R., Horsfall, L., et al. Awareness and opinions of non-alcoholic fatty liver disease by hospital specialists. Intern Med J 43 (2013), 247–253.
45. [45] Ghevariya, V., Sandar, N., Patel, K., et al. Knowing what's out there: awareness of non-alcoholic fatty liver disease. Front Med (Lausanne), 1, 2014, 4.
46. [46] Wieland, A.C., Mettler, P., McDermott, M.T., et al. Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk. J Clin Gastroenterol 49 (2015), e6–e10.